• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Overview Of Value Stocks In The Healthcare Sector

    2/12/24 9:43:58 AM ET
    $BNTX
    $NUWE
    $QNRX
    $SYRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $BNTX alert in real time by email

    The Meaning Behind Value Stocks

    A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

    Below is a list of notable value stocks in the healthcare sector:

    1. Quoin Pharmaceuticals (NASDAQ:QNRX) - P/E: 2.43
    2. BioNTech (NASDAQ:BNTX) - P/E: 7.66
    3. Nuwellis (NASDAQ:NUWE) - P/E: 0.02
    4. TherapeuticsMD (NASDAQ:TXMD) - P/E: 0.47
    5. Syros Pharmaceuticals (NASDAQ:SYRS) - P/E: 8.32

    Quoin Pharmaceuticals saw an increase in earnings per share from -2.13 in Q2 to $-1.95 now. Most recently, BioNTech reported earnings per share at $0.73, whereas in Q2 earnings per share sat at $-0.86. Most recently, Nuwellis reported earnings per share at $-1.81, whereas in Q2 earnings per share sat at $-3.65. TherapeuticsMD's earnings per share for Q3 sits at $-0.13, whereas in Q2, they were at -0.24. This quarter, Syros Pharmaceuticals experienced a decrease in earnings per share, which was $-1.3 in Q2 and is now $-1.43.

    These 5 value stocks were selected by Benzinga Insights based on quantified analysis. While this methodical judgment process is not meant to make final decisions, our technology can give investors additional perception into the sector.

    Get the next $BNTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BNTX
    $NUWE
    $QNRX
    $SYRS

    CompanyDatePrice TargetRatingAnalyst
    BioNTech SE
    $BNTX
    2/2/2026$113.00Outperform → Market Perform
    Leerink Partners
    BioNTech SE
    $BNTX
    1/16/2026$142.00Neutral → Buy
    Goldman
    BioNTech SE
    $BNTX
    6/5/2025$134.00 → $145.00Buy
    H.C. Wainwright
    BioNTech SE
    $BNTX
    5/29/2025$110.00Neutral
    Goldman
    BioNTech SE
    $BNTX
    3/13/2025$145.00Buy
    Citigroup
    BioNTech SE
    $BNTX
    1/10/2025$172.00Buy
    Truist
    BioNTech SE
    $BNTX
    12/11/2024$170.00Overweight
    Wells Fargo
    BioNTech SE
    $BNTX
    12/2/2024Outperform
    BMO Capital Markets
    More analyst ratings

    $BNTX
    $NUWE
    $QNRX
    $SYRS
    SEC Filings

    View All

    Nuwellis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Nuwellis, Inc. (0001506492) (Filer)

    3/10/26 4:02:58 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 20-F filed by BioNTech SE

    20-F - BioNTech SE (0001776985) (Filer)

    3/10/26 6:55:57 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by BioNTech SE

    6-K - BioNTech SE (0001776985) (Filer)

    3/10/26 6:53:33 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BNTX
    $NUWE
    $QNRX
    $SYRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BioNTech downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded BioNTech from Outperform to Market Perform and set a new price target of $113.00

    2/2/26 6:48:45 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioNTech upgraded by Goldman with a new price target

    Goldman upgraded BioNTech from Neutral to Buy and set a new price target of $142.00

    1/16/26 8:19:35 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright reiterated coverage on BioNTech with a new price target

    H.C. Wainwright reiterated coverage of BioNTech with a rating of Buy and set a new price target of $145.00 from $134.00 previously

    6/5/25 11:30:01 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BNTX
    $NUWE
    $QNRX
    $SYRS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for BIJUVA issued to THERAPEUTICSMD INC

    Submission status for THERAPEUTICSMD INC's drug BIJUVA (SUPPL-6) with active ingredient ESTRADIOL; PROGESTERONE has changed to 'Approval' on 12/28/2021. Application Category: NDA, Application Number: 210132, Application Classification: Efficacy

    12/29/21 7:23:57 AM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for IMVEXXY issued to THERAPEUTICSMD INC

    Submission status for THERAPEUTICSMD INC's drug IMVEXXY (SUPPL-2) with active ingredient ESTRADIOL has changed to 'Approval' on 11/16/2021. Application Category: NDA, Application Number: 208564, Application Classification: Labeling

    11/17/21 4:38:32 AM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for BIJUVA issued to THERAPEUTICSMD INC

    Submission status for THERAPEUTICSMD INC's drug BIJUVA (SUPPL-3) with active ingredient ESTRADIOL; PROGESTERONE has changed to 'Approval' on 06/22/2021. Application Category: NDA, Application Number: 210132, Application Classification: Labeling

    6/24/21 5:13:50 AM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNTX
    $NUWE
    $QNRX
    $SYRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Mcdonald David

    3 - Nuwellis, Inc. (0001506492) (Issuer)

    3/2/26 4:08:18 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by new insider Schultz Carisa

    3 - Nuwellis, Inc. (0001506492) (Issuer)

    2/12/26 4:15:30 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by new insider Field Katharyn

    3 - Nuwellis, Inc. (0001506492) (Issuer)

    2/11/26 3:35:38 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BNTX
    $NUWE
    $QNRX
    $SYRS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thompson Tommy G bought $14,031 worth of shares (8,400 units at $1.67), increasing direct ownership by 57% to 23,179 units (SEC Form 4)

    4 - TherapeuticsMD, Inc. (0000025743) (Issuer)

    12/29/25 4:23:31 PM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Langer Dennis bought $128,640 worth of ADSs (15,152 units at $8.49), increasing direct ownership by 1,515,200% to 15,153 units (SEC Form 4)

    4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

    10/15/25 5:15:20 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Director Thompson Tommy G bought $326 worth of shares (325 units at $1.00), increasing direct ownership by 2% to 14,779 units (SEC Form 4)

    4 - TherapeuticsMD, Inc. (0000025743) (Issuer)

    4/15/25 7:59:38 AM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNTX
    $NUWE
    $QNRX
    $SYRS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome

    — Fast Track Designation facilitates development and expedites regulatory review of therapies addressing serious conditions with significant unmet medical need — — QRX003 lotion (4%) currently being evaluated in two late-stage whole-body clinical trials for treatment of Netherton Syndrome — — Fast Track Designation follows Pediatric Rare Disease and Orphan Drug Designation previously granted by the FDA and Orphan Drug Designation granted by the European Medicines Agency for QRX003 in Netherton Syndrome — ASHBURN, Va., March 11, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on d

    3/11/26 8:30:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results

    MINNEAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Recent Highlights: Fourth quarter revenue of $2.4 million, a 4% increase compared to the prior-year quarter and 9% increase sequentially.208% increase in U.S. console sales in Q4 versus prior year quarter.Heart Failure revenue increased 48% and Pediatrics increased 16% year-over-year in Q4.Gross margin of 68.2% in Q4, compared to 58.4% in the prior-year quarter.Closed a $5.0 million private p

    3/10/26 8:15:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

    BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on PD-L11/VEGF-A bispecific immunomodulator pumitamig with eight global Phase 3 clinical trials planned to be ongoing for year-end in collaboration with Bristol Myers Squibb Full year 2025 revenues of €2.9 billion2, net loss of €1.1 billion (adjusted3 net loss of €0.1 billion) and diluted loss per share of €4.70 ($5.314) (adjusted3 diluted loss per share of €0.48 ($0.554)) Strong financial position continues to de-risk execution with cash, cash equivalents and security investments of €17.2 billion5Expect 202

    3/10/26 6:45:00 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BNTX
    $NUWE
    $QNRX
    $SYRS
    Leadership Updates

    Live Leadership Updates

    View All

    Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal Strategy

    MINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Stuart L. Goldstein, MD, FASN as Director of Clinical Strategy. Dr. Goldstein is internationally recognized as a pioneer in pediatric nephrology and critical care medicine. He serves as Director of the Center for Acute Care Nephrology, holds the Clark D. West Endowed Chair in Pediatric Nephrology at Cincinnati Children's Hospital Medical Center and is Professor of Pediatrics at the University of Cincinnati College of Medicine. His work has helped define the modern understand

    3/5/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors

    MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company's board with complementary expertise in public company leadership, capital markets, and medical device commercialization. "These appointments reflect our continued focus on operational discipline and long-term value creation," said John Erb, President and CEO of Nuwellis. "Marty has led multiple medical device organizations through scali

    2/26/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Appoints Carisa Schultz as Chief Financial Officer

    MINNEAPOLIS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE) a medical technology company focused on advancing precision cardiorenal care, today announced the appointment of Carisa Schultz as Chief Financial Officer, effective February 2, 2026. Ms. Schultz brings extensive healthcare and public company finance leadership experience, most recently serving as Vice President of Finance at NeueHealth (formerly Bright Health Group), a healthcare company previously listed on the New York Stock Exchange. In that role, she led enterprise finance, treasury, and corporate development activities. During her tenure at NeueHealth, she also held progressive leadership roles including A

    1/30/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BNTX
    $NUWE
    $QNRX
    $SYRS
    Financials

    Live finance-specific insights

    View All

    Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results

    MINNEAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Recent Highlights: Fourth quarter revenue of $2.4 million, a 4% increase compared to the prior-year quarter and 9% increase sequentially.208% increase in U.S. console sales in Q4 versus prior year quarter.Heart Failure revenue increased 48% and Pediatrics increased 16% year-over-year in Q4.Gross margin of 68.2% in Q4, compared to 58.4% in the prior-year quarter.Closed a $5.0 million private p

    3/10/26 8:15:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

    BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on PD-L11/VEGF-A bispecific immunomodulator pumitamig with eight global Phase 3 clinical trials planned to be ongoing for year-end in collaboration with Bristol Myers Squibb Full year 2025 revenues of €2.9 billion2, net loss of €1.1 billion (adjusted3 net loss of €0.1 billion) and diluted loss per share of €4.70 ($5.314) (adjusted3 diluted loss per share of €0.48 ($0.554)) Strong financial position continues to de-risk execution with cash, cash equivalents and security investments of €17.2 billion5Expect 202

    3/10/26 6:45:00 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Nuwellis, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026

    MINNEAPOLIS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it will release financial results for the fourth quarter and full year 2025 on March 10, 2026. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-800-343-4885 (U.S) or 1-203-518-9851 (international) and using the conference ID: N

    2/24/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BNTX
    $NUWE
    $QNRX
    $SYRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Quoin Pharmaceuticals Ltd.

    SC 13G/A - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)

    11/14/24 7:23:29 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Syros Pharmaceuticals Inc.

    SC 13G/A - Syros Pharmaceuticals, Inc. (0001556263) (Subject)

    11/14/24 5:28:08 PM ET
    $SYRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Syros Pharmaceuticals Inc.

    SC 13G/A - Syros Pharmaceuticals, Inc. (0001556263) (Subject)

    11/14/24 5:24:48 PM ET
    $SYRS
    Biotechnology: Pharmaceutical Preparations
    Health Care